The risk of coronary artery disease (CAD) is traditionally considered high in patients who had an ischemic stroke or a transient ischemic attack (TIA). However, few studies have specifically assessed the absolute risk of coronary events in those patients and predictors of such events are not well known.
Summary of review
The overall risks of myocardial infarction and nonstroke vascular death are each around 2% per year. However, those risks are only about 1% per year in patients without CAD (i.e. the only ones who are likely to benefit from specific additional strategies). The prevalence of asymptomatic CAD ranges from 15% to 60%. Although potentially higher, the risk of CAD in patients with stroke/TIA related to atherosclerosis also seems to vary widely depending on the extent of the disease. Given the relatively low CAD risk, a simple systematic reinforcement of medical treatment in all patients may be not relevant. Up to now, there have been only limited ways to stratify the CAD risk in stroke/TIA patients. High-risk patients may be identified using the traditional cardiac scoring systems, but their validity has never been specifically assessed in stroke populations. The relative influence of traditional risk factors may be altered after a first vascular event. Stroke patients could also be screened for asymptomatic CAD. However, there is no simple and valid screening test for asymptomatic CAD that could be applied to all patients. Finally, there is still uncertainty about the potential benefits of treating asymptomatic CAD. Therefore, should the identification of patients with asymptomatic CAD requiring revascularization become feasible, the relevance of this strategy would remain to be evaluated by a randomized clinical trial.
Conclusion
The absolute risk of CAD in stroke/TIA patients is moderately high. More research is needed to identify high risk patients who could benefit from specific strategies.
Get full access to this article
View all access options for this article.
References
1.
AdamsRJChimowitzMIAlpertJS. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: A scientific statement for healthcare professionals from the stroke council and the Council on clinical cardiology of the American Heart Association/American Stroke Association. Circulation2003; 108: 1278–90.
2.
TouzéEVarenneOChatellierGPeyrardSRothwellPMMasJL: Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: A systematic review and meta-analysis. Stroke2005; 36: 2748–55.
3.
MathurKSKashyapSKKumarV: Correlation of the extent and severity of atherosclerosis in the coronary and cerebral arteries. Circulation1963; 27: 929–34.
4.
SolbergLAMcGarryPAMoossyJStrongJPTejadaCLökenAC: Severity of atherosclerosis in cerebral arteries, coronary arteries, and aortas. Ann NY Acad Sci1968; 149: 956–73.
5.
DhamoonMSSciaccaRRRundekTSaccoRLElkindMS: Recurrent stroke and cardiac risks after first ischemic stroke: The Northern Manhattan study. Neurology2006; 66: 641–6.
6.
The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet1997; 349: 1569–81.
7.
GrottaJ: Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke1997; 28: 2338–46.
8.
DienerHCCortensMFordG. Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke2000; 31: 2543–51.
9.
ShermanDGAtkinsonRPChippendaleT. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial. Stroke treatment with ancrod trial. JAMA2000; 283: 2395–403.
10.
BathPMIddendenRBathFJ: Low-molecular-weight heparins and heparinoids in acute ischemic stroke: A meta-analysis of randomized controlled trials. Stroke2000; 31: 1770–8.
11.
BathPMLindenstromEBoysenG. Tinzaparin in acute ischaemic stroke (TAIST): A randomised aspirin-controlled trial. Lancet2001; 358: 702–10.
12.
MuirKWLeesKRFordIDavisS: Magnesium for acute stroke (intravenous magnesium efficacy in stroke trial): Randomised controlled trial. Lancet2004; 363: 439–45.
13.
BamfordJDennisMSandercockPBurnJWarlowC: The frequency, causes and timing of death within 30 days of a first stroke: The Oxfordshire community stroke project. J Neurol Neurosurg Psychiatry1990; 53: 824–9.
14.
DienerHCRingelsteinEBVonKR. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: Results of the TOPAS trial. Therapy of patients with acute stroke (TOPAS) investigators. Stroke2001; 32: 22–9.
15.
HartmannARundekTMastH. Mortality and causes of death after first ischemic stroke. The Northern Manhattan stroke study. Neurology2001; 57: 2000–5.
16.
VerninoSBrownRDSejvarJJSicksJDPettyGWO'FallonM: Cause-specific mortality after first cerebral infarction. A population-based study. Stroke2003; 34: 1828–32.
17.
HankeyGJJamrozikKBroadhurstRJ. Five-year survival after first-ever stroke and related prognostic factors in the Perth community stroke study. Stroke2000; 31: 2080–6.
18.
SenSOppenheimerSM: Cardiac disorders and stroke. Curr Opin Neurol1998; 11: 51–6.
19.
HachinskiVCSmithKESilverMDGibsonCJCirielloJ: Acute myocardial and plasma catecholamine changes in experimental stroke. Stroke1986; 17: 387–90.
20.
HachinskiVCSmithKESilverMDGibsonCJCirielloJ: Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J1998; 19: 1434–503.
21.
GrundySMPasternakRGreenlandPSmithSJrFusterV: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation1999; 100: 1481–92.
22.
BrownDLLisabethLDRoychoudhuryCYeYMorgensternLB: Recurrent stroke risk is higher than cardiac event risk after initial stroke/transient ischemic attack. Stroke2005; 36: 1285–7.
23.
van WijkIKappelleLJvan GijnJ. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: A cohort study. Lancet2005; 365: 2098–104.
24.
AmarencoPBogousslavskyJCallahanAIII. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med2006; 355: 549–59.
25.
TouzéEMasJLRötherJ. Risk of vascular death and myocardial infarction in patients with stroke or TIA: Results from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Cerebrovasc Dis2006; 21: 55.
26.
RokeyRRolakLAHaratiYKurkaNVeraniMS: Coronary artery disease in patients with cerebrovascular disease: A prospective study. Ann Neurol1984; 16: 50–3.
27.
Di PasqualeGPinelliGGraziP. Incidence of silent myocardial ischaemia in patients with cerebral ischaemia. Eur Heart J1988; 9: 104–7.
28.
Di PasqualeGAndreoliACariniG. Noninvasive screening for silent ischemic heart disease in patients with cerebral ischemia: Use of dipyridamole–thallium myocardial imaging. Cerebrovasc Dis1991; 1: 31–7.
29.
LoveBBGrover-McKayMBillerJRezaiKMcKayCR: Coronary artery disease and cardiac events with asymptomatic and symptomatic cerebrovascular disease. Stroke1992; 23: 939–45.
30.
UrbinatiSDi PasqualeGAndreoliA. Frequency and prognostic significance of silent coronary artery disease in patients with cerebral ischemia undergoing endarterectomy. Am J Cardiol1992; 69: 1166–70.
31.
ChimowitzMIPooleRMStarlingMRSchwaigerMGrossMD: Frequency and severity of asymptomatic coronary disease in patients with different causes of stroke. Stroke1997; 28: 941–5.
ArenillasJFCandell-RieraJRomero-FarinaG. Silent myocardial ischemia in patients with symptomatic intracranial atherosclerosis: Associated factors. Stroke2005; 36: 1201–6.
34.
NighoghossianNCakmakSDerexL. Silent coronaropathy: Usefulness of dobutamine stress echocardiography in ischemic stroke. Eur Neurol2006; 56: 211–6.
35.
HertzerNRYoungJRBevenEG. Coronary angiography in 506 patients with extracranial cerebrovascular disease. Arch Intern Med1985; 145: 849–52.
36.
Gongora-RiveraFLabreucheJJaramilloAStegPGHauwJJAmarencoP: Autopsy prevalence of coronary atherosclerosis in patients with fatal stroke. Stroke2007; 38: 1203–1210.
37.
SmithSCJrAmsterdamEBaladyGJ. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Tests for silent and inducible ischemia: Writing group II. Circulation2000; 101: E12–6.
38.
ConroyRMPyoralaKFitzgeraldAP. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J2003; 24: 987–1003.
39.
WilsonPWD'AgostinoRBLevyDBelangerAMSilbershatzHKannelWB: Prediction of coronary heart disease using risk factor categories. Circulation1998; 97: 1837–47.
40.
D'AgostinoRBRussellMWHuseDM. Primary and subsequent coronary risk appraisal: New results from the Framingham study. Am Heart J2000; 139: 272–81.
41.
BogousslavskyJVan MelleGRegliF: The lausanne stroke registry: Analysis of 1,000 consecutive patients with first stroke. Stroke1988; 19: 1083–92.
42.
GrauAJWeimarCBuggleF. Risk factors, outcome, and treatment in subtypes of ischemic stroke: The German stroke data bank. Stroke2001; 32: 2559–66.
43.
JoakimsenOBonaaKHMathiesenEBStensland-BuggeEArnesenE: Prediction of mortality by ultrasound screening of general population for carotid stenosis. The Tromso study. Stroke2000; 31: 1871–6.
44.
Kolominsky-RabasPLWeberMGefellerONeundoerferBHeuschmannPU: Epidemiology of ischemic stroke subtypes according to TOAST criteria. Incidence, recurrence, and long-term survival in ischemic stroke subtypes: A population-based study. Stroke2001; 32: 2735–40.
45.
LongstrethWTJrBernickCFitzpatrickA. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology2001; 56: 368–75.
46.
PettyGWBrownRDJrWhisnantJPSicksJDO'FallonWMWiebersDO: Survival and recurrence after first cerebral infarction: A population-based study in Rochester, Minnesota, 1975 through 1989. Neurology1998; 50: 208–16.
47.
Gates PC, Eliasziw M, Algra A, Barnett HJM, Gunton RW: For the North American symptomatic carotid endarterectomy trial group. Identifying patients with symptomatic carotid artery disease at high and low risk of severe myocardial infarction and cardiac death. Stroke2002; 33: 2413–6.
48.
TouzéEWarlowCPRothwellPM: Risk of coronary and other nonstroke vascular death in relation to the presence and extent of atherosclerotic disease at the carotid bifurcation. Stroke2006; 37: 2904–9.
49.
MalekAMAlperSLIzumoS: Hemodynamic shear stress and its role in atherosclerosis. JAMA1999; 282: 2035–42.
50.
ShaabanAMDuerinckxAJ: Wall shear stress and early atherosclerosis: A review. Am J Roentgenol2000; 174: 1657–65.
51.
SitzerMPuacDBuehlerA. Internal carotid artery angle of origin: A novel risk factor for early carotid atherosclerosis. Stroke2003; 34: 950–5.
52.
GnassoAIraceCCaralloC. In vivo association between low wall shear stress and plaque in subjects with asymmetrical carotid atherosclerosis. Stroke1997; 28: 993–8.
53.
AdamsGJSimoniDMBordelonCBJr. Bilateral symmetry of human carotid artery atherosclerosis. Stroke2002; 33: 2575–80.
54.
VinkASchoneveldAHRichardW. Plaque burden, arterial remodeling and plaque vulnerability: Determined by systemic factors?J Am Coll Cardiol2001; 38: 718–23.
55.
DienerHCBogousslavskyJBrassLM. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet2004; 364: 331–7.
56.
JacksonCSudlowC: Are lacunar strokes really different? A systematic review of differences in risk factor profiles between lacunar and nonlacunar infarcts. Stroke2005; 36: 891–901.
57.
DeweyMTeigeFSchnapauffD. Noninvasive detection of coronary artery stenoses with multislice computed tomography or magnetic resonance imaging. Ann Intern Med2006; 145: 407–15.
58.
HamonMBiondi-ZoccaiGGMalaguttiP. Diagnostic performance of multislice spiral computed tomography of coronary arteries as compared with conventional invasive coronary angiography: A meta-analysis. J Am Coll Cardiol2006; 48: 1896–910.
59.
EagleKAGuytonRADavidoffR. ACC/AHA guidelines for coronary artery bypass graft surgery: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation1999; 100: 1464–80.
